>MEA CAR-T 세포 치료 시장, 제품별(자가 CAR-T 세포 및 이종이식 CAR-T 세포), 구조(1세대 CAR-T 세포, 2세대 Car-T 세포, 3세대 CAR-T 세포 및 4세대 CAR-T 세포), 표적 항원(고형 종양 항원, 혈액 악성 종양 항원 및 기타), 브랜드(Yescarta, Kymriah, Tecartus 및 기타), 치료적 적용(확산성 대형 B세포 림프종, 모낭 림프종, 급성 림프모구 백혈병(ALL), 맨틀 세포 림프종, 다발성 골수종, 혈액 악성 종양, 폐암, 만성 림프구성 백혈병, 위암, 췌장암, 유방암 및 기타), 최종 사용자(병원, 전문 병원 및 기타), 유통 채널(병원 약국 및 기타)- 2031년까지의 업계 동향 및 전망.
MEA CAR-T 세포 치료 시장 분석 및 규모
MEA 지역에서 암 유병률이 증가하는 것은 Car-T 세포 치료 시장의 주요 원동력으로, 더 효과적인 치료에 대한 필요성이 커지고 있습니다. 그러나 Car-T 세포 치료의 높은 비용은 상당한 장벽을 제시하여 접근성을 제한할 가능성이 있습니다. 긍정적인 측면에서, 특히 싱가포르와 같은 국가에서 의료 인프라 개발과 의료 관광에 대한 지역적 집중이 증가함에 따라 시장 성장의 기회가 있습니다. 그럼에도 불구하고, 이 지역에서 Car-T 세포 치료의 장기적 효능과 안전성을 확립하기 위한 광범위한 연구와 임상 시험이 필요하다는 것이 주요 과제입니다.
Data Bridge Market Research에 따르면 MEA CAR-T 세포 치료 시장은 2031년까지 1억 569만 달러에 도달할 것으로 예상되며, 2027년부터 2031년까지의 예측 기간 동안 연평균 성장률은 30.7%로 성장할 것으로 예상됩니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2027년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
제품(자가 CAR-T 세포 및 이종이식 CAR-T 세포), 구조(1세대 CAR-T 세포, 2세대 Car-T 세포, 3세대 CAR-T 세포 및 4세대 CAR-T 세포), 표적 항원(고형 종양 항원, 혈액 악성 종양 항원 및 기타), 브랜드(Yescarta, Kymriah, Tecartus 및 기타), 치료적 적용(확산성 대형 B세포 림프종, 모낭 림프종, 급성 림프모구 백혈병(ALL), 맨틀 세포 림프종, 다발성 골수종, 혈액 악성 종양, 폐암, 만성 림프구성 백혈병, 위암, 췌장암, 유방암 및 기타), 최종 사용자(병원, 전문 병원 및 기타), 유통 채널(병원 약국 및 기타) |
|
적용 국가 |
사우디 아라비아, 남아프리카, UAE, 이스라엘, 쿠웨이트, 이집트 및 기타 중동 및 아프리카 |
|
시장 참여자 포함 |
Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc. 등 |
Market Definition
CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. These receptors are chimeric because they are combined with both antigen-binding and T-cell activating functions into a single receptor. Once the CAR-T cells infused in the patient’s body then they act as a “living cell” which has the ability or designed in such a way that they can kill the harmful cancer cells without affecting the healthy cells. The CAR-T cells when comes in contact with the targeted antigen on a cell, CAR-T cells binds with it and becomes activated and multiply to become cytotoxic.
MEA CAR-T Cell Therapy Treatment Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Cancer and other Target Diseases
Cancer is a leading cause of morbidity and mortality worldwide, and the incidence of cancer is rising in these regions due to factors such as population growth, aging, and lifestyle changes. Additionally, there is a growing burden of other target diseases, such as hematological disorders, which can also be treated with CAR-T cell therapy. This increasing disease burden underscores the need for innovative and effective treatments like CAR-T cell therapy, driving market growth.
- Growing Awareness and Acceptance of Car-T Cell Therapy
The growing awareness and acceptance of CAR-T cell therapy as an effective treatment in the MEA, Saudi Arabia, and MEA regions are driven by various factors. These include heightened media coverage, educational efforts by healthcare organizations, and the sharing of success stories that highlight the therapy's effectiveness. Consequently, patients and healthcare providers are gaining a better understanding of CAR-T cell therapy's potential advantages, such as higher response rates and long-lasting remissions, especially in cases that are refractory or have relapsed. Additionally, regulatory approvals and endorsements in these regions have cemented CAR-T cell therapy's status as a legitimate and viable treatment option.
Opportunity
- The Extensive Pipeline of Car-T Cell Therapy
The extensive pipeline represents a wealth of opportunities for patients, healthcare providers, and the healthcare industry as a whole. This pipeline includes a range of CAR-T cell therapy products in various stages of development, from early preclinical Research to advanced clinical trials. The pipeline reflects ongoing innovation and investment in CAR-T cell therapy, with new products being developed to target different types of cancer and hematological disorders. Additionally, the pipeline includes products aimed at improving the safety, efficacy, and accessibility of CAR-T cell therapy, such as next-generation CAR-T cell therapies and off-the-shelf CAR-T cell products.
Restraints/Challenges
- High Cost of Car-T Cell Therapy
CAR-T cell therapy is a highly personalized and complex treatment that involves modifying a patient's immune cells to target cancer cells, making it a costly procedure. Factors contributing to this high cost include the specialized manufacturing process, extensive clinical monitoring, and infrastructure requirements. As a result, many patients, particularly those without adequate insurance coverage or financial resources, face challenges accessing this innovative therapy. The cost of clinical trials, regulatory compliance, and post-treatment monitoring further increases the overall expense, highlighting the financial burden for patients, especially those from lower-income backgrounds.
- Potential Risks and Adverse Effects of Treatment
CAR-T cell therapy, despite its promising efficacy, presents potential risks and side effects that pose challenges for patients and healthcare providers in the MEA, Saudi Arabia, and MEA regions. The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. CRS, a significant adverse effect, occurs when infused CAR T cells recognize and attack cancer cells, leading to the release of cytokines like interleukin-6 (IL-6). This immune response causes systemic inflammation, manifesting in symptoms from mild fever and flu-like symptoms to potentially life-threatening complications like hypotension, respiratory distress, and multiorgan failure. CAR T-cell therapy can also trigger immune effector cell-associated neurotoxicity syndrome (ICANS), characterized by neurological symptoms such as confusion, seizures, and impaired speech. These side effects result from immune system overactivation and cytokine release, emphasizing the need for vigilant monitoring and prompt management to ensure patient safety and treatment efficacy.
Recent Developments
- In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
- In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
- In February 2022, the FDA has approved CARVYKTI™ (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
- In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform
MEA CAR-T Cell Therapy Treatment Market Scope
The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells.
Structure
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells.
Targeted Antigens
- Antigens on Solid Tumors
- Antigens on Hematologic Malignancies
- Others
On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others.
Brand
- Yescarta
- Kymriah
- Tecartus
- Others
On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others.
Therapeutic Application
- Hematological Malignancies
- Pancreatic Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukemia (ALL)
- Others
치료적 적용을 기준으로 시장은 확산성 대세포 B 세포 림프종, 모낭성 림프종, 급성 림프모구 백혈병(ALL), 맨틀세포 림프종, 다발성 골수종, 혈액 악성 종양, 폐암, 만성 림프구성 백혈병, 위암, 췌장암, 유방암 등으로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 기타
최종 사용자를 기준으로 시장은 병원, 전문 병원 및 기타로 구분됩니다.
유통 채널
- 병원 약국
- 기타
유통 채널을 기준으로 시장은 병원, 약국 및 기타로 세분화됩니다.
MEA CAR-T 세포 치료 치료 시장 지역 분석/통찰력
MEA CAR-T 세포 치료 시장은 제품, 구조, 표적 항원, 브랜드, 치료적 적용, 최종 사용자 및 유통 채널을 기준으로 7개의 주요 세그먼트로 구분됩니다.
이 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 쿠웨이트, 이집트, 그리고 나머지 중동 및 아프리카 국가입니다.
사우디아라비아는 선진 의료 인프라, 정부 지원, 성장하는 의료 관광 부문, 연구 개발 활동, 선진 치료에 대한 수요 증가 등으로 인해 MEA CAR-T 세포 치료 시장을 장악할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 지역 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제와 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 MEA CAR-T 세포 치료 시장 점유율 분석
MEA CAR-T 세포 치료제 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 응용 프로그램 우세 및 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.
시장에서 활동하는 주요 기업으로는 Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF CANCER AND OTHER TARGET DISEASES
5.1.2 GROWING AWARENESS AND ACCEPTANCE OF CAR-T CELL THERAPY
5.1.3 SUPPORTIVE GOVERNMENT INITIATIVES AND FUNDING FOR HEALTHCARE INNOVATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF CAR-T CELL THERAPY
5.2.2 REGULATORY HURDLES RESULT THE DELAY IN CAR T-CELL THERAPY APPROVAL
5.3 OPPORTUNITIES
5.3.1 THE EXTENSIVE PIPELINE OF CAR-T CELL THERAPY
5.3.2 THE DEVELOPMENT OF NOVEL THERAPIES AND COMBINATION TREATMENTS
5.4 CHALLENGES
5.4.1 POTENTIAL RISKS AND ADVERSE EFFECTS OF TREATMENT
5.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS AND THERAPIES
6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENTN MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 AUTOLOGOUS CAR-T CELLS
6.3 ALLOGENEIC CAR-T CELLS
7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY STRUCTURE
7.1 OVERVIEW
7.2 SECOND GENERATION CAR-T CELLS
7.3 THIRD GENERATION CAR-T CELLS
7.4 FOURTH GENERATION CAR-T CELLS
7.5 FIRST GENERATION CAR-T CELLS
8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
8.1 OVERVIEW
8.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
8.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
8.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
8.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
8.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
8.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
8.3 ANTIGENS ON SOLID TUMORS
8.4 OTHERS
9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY BRAND
9.1 OVERVIEW
9.2 KYMRIAH
9.3 YESCARTA
9.4 TECARTUS
9.5 OTHERS
10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY THERAPEUTICS APPLICATION
10.1 OVERVIEW
10.2 DIFFUSE LARGE B-CELL LYMPHOMA
10.3 FOLLICULAR LYMPHOMA
10.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
10.5 MANTLE CELL LYMPHOMA
10.6 MULTIPLE MYELOMA
10.7 LUNG CANCER
10.8 CHRONIC LYMPHOCYTIC LEUKEMIA
10.9 GASTRIC CANCER
10.1 PANCREATIC CANCER
10.11 BREAST CANCER
10.12 OTHERS
11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 OTHERS
12 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY, DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 OTHERS
13 MEA, SAUDI ARABIA, SEA CAR-T CELL THERAPY MARKET, BY COUNTRY
13.1 MEA
13.1.1 SAUDI ARABIA
13.1.2 U.A.E.
13.1.3 SOUTH AFRICA
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
13.2 SEA
13.2.1 SINGAPORE
13.2.2 MALAYSIA
13.2.3 THAILAND
13.2.4 INDONESIA
13.2.5 PHILIPPINES
13.2.6 VIETNAM
14 MEA AND SEA CAR-T CELL THERAPY MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MEA
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 NOVARTIS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 GILEAD SCIENCES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 BRISTOL-MYERS SQUIBB COMPANY
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 JOHNSON & JOHNSON SERVICES, INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA)
TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
그림 목록
FIGURE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET
FIGURE 14 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 15 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 16 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 17 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 18 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2027-2031)
FIGURE 19 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 21 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2024-2031)
FIGURE 22 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 23 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 24 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2027-2031)
FIGURE 25 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 27 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, CAGR (2024-2031)
FIGURE 28 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 29 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 30 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, CAGR (2027-2031)
FIGURE 31 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 32 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 33 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2024-2031)
FIGURE 34 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 35 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 36 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, CAGR (2027-2031)
FIGURE 37 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, LIFELINE CURVE
FIGURE 38 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 39 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, CAGR (2024-2031)
FIGURE 40 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 41 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 42 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, CAGR (2027-2031)
FIGURE 43 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 44 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 45 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 48 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2027-2031)
FIGURE 49 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 50 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 51 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 52 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 54 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2027-2031)
FIGURE 55 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 MEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 57 SEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 58 MEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 59 SEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
